<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24528" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Discoid Lupus Erythematosus</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>McDaniel</surname>
            <given-names>Brianna</given-names>
          </name>
          <aff>Sampson Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sukumaran</surname>
            <given-names>Sukesh</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Koritala</surname>
            <given-names>Thoyaja</given-names>
          </name>
          <aff>Mayo Clinic</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tanner</surname>
            <given-names>Laura S.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Brianna McDaniel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sukesh Sukumaran declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Thoyaja Koritala declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Laura Tanner declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24528.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Lupus erythematosus is a multisystem disorder that predominately affects the skin. There are several types of cutaneous lupus. The most common types are acute cutaneous lupus (ACLE), subacute cutaneous lupus (SCLE), and discoid lupus (DLE). Dr. James Gilliam described the most commonly used classification of cutaneous lesions in lupus erythematosus. Gilliam segregated skin lesions into those that are specific and those that are not specifically based upon whether an interface dermatitis was seen on histopathologic examination. This activity reviews the pathophysiology of discoid lupus, its presentation, and management by an interprofessional team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe how genetic and environmental factors play an important role in the pathogenesis of DLE.</p></list-item><list-item><p>Review the categorization of the lesions associated with DLE.</p></list-item><list-item><p>Summarize how topical and intralesional corticosteroids, oral corticosteroids, oral antimalarials, and corticosteroid-sparing immunomodulatory agents are used for treating DLE lesions.</p></list-item><list-item><p>Explain how monitoring adverse effects of the medications by all interprofessional team members is crucial for a patient's comprehensive recovery.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24528&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24528">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24528.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Lupus erythematosus is a multisystem disorder that predominantly affects the skin. There are several types of cutaneous lupus. The most common types are acute cutaneous lupus (ACLE), subacute cutaneous lupus (SCLE), and discoid lupus (DLE). Dr. James Gilliam described the most commonly used classification of cutaneous lesions in lupus erythematosus. Gilliam segregated skin lesions into those that are specific and those that are not specifically based upon whether an interface dermatitis was seen on histopathologic examination. Within the category of specific cutaneous lesions, he subdivided these into&#x000a0;acute cutaneous lupus&#x000a0;erythematosus,&#x000a0;subacute cutaneous lupus&#x000a0;erythematosus, and chronic cutaneous&#x000a0;erythematosus.<xref ref-type="bibr" rid="article-24528.r1">[1]</xref><xref ref-type="bibr" rid="article-24528.r2">[2]</xref></p>
        <p>The most common subset of chronic cutaneous lupus erythematosus is DLE. These patients may or may not report photosensitivity, but lesions are frequently photo distributed and tend to have secondary atrophy or scarring. Most patients with DLE do not have significant systemic disease. DLE can also occur as a manifestation of SLE in approximately 20% of patients. Other less common forms of chronic cutaneous&#x000a0;lupus erythematosus&#x000a0;include hypertrophic&#x000a0;lupus erythematosus, tumid&#x000a0;lupus erythematosus, lupus erythematosus panniculitis (LEP or lupus profundus), chilblain LE, oral DLE, as well as DLE lesions on the palms and/or soles.<xref ref-type="bibr" rid="article-24528.r3">[3]</xref><xref ref-type="bibr" rid="article-24528.r4">[4]</xref></p>
      </sec>
      <sec id="article-24528.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Lupus erythematosus is an inflammatory, connective-tissue disease of generalized autoimmunity characterized by pathogenic autoantibodies and immune complexes, attributed to a loss of immune tolerance. For discoid lupus erythematosus without associated SLE (CDLE), the evidence does not show whether circulating inflammatory cells and autoantibodies are involved in the pathogenesis, but it is evident that&#x000a0;the cutaneous inflammatory infiltrates are dominated by Th1, but not Th17, cells in contrast to systemic lupus erythematosus.<xref ref-type="bibr" rid="article-24528.r5">[5]</xref><xref ref-type="bibr" rid="article-24528.r6">[6]</xref></p>
      </sec>
      <sec id="article-24528.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Lupus can occur in all age groups, but DLE occurs more frequently in women in their fourth and fifth decades of life. Twenty-five percent of patients with SLE may develop typical discoid lesions at some point&#x000a0;during their illness, and 1% to 5% of patients with discoid lupus may develop SLE.</p>
        <p>Ethnicity is also a major risk factor for developing LE, and its effect in some populations is almost as strong as that of gender. SLE prevalence is four-fold higher in African-American women than White-race American women (4 in 1000 versus 1 in 1000). In addition, African-Americans tend to&#x000a0;develop the disease at an earlier age and have a higher mortality rate.<xref ref-type="bibr" rid="article-24528.r7">[7]</xref><xref ref-type="bibr" rid="article-24528.r8">[8]</xref></p>
      </sec>
      <sec id="article-24528.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathogenesis of cutaneous lupus erythematosus&#x000a0;is multifactorial, with an interplay between genetic and environmental factors. Some contributing environmental factors include ultraviolet radiation (UVR), medications, cigarette smoking, and possibly, viruses. The interaction between these multiple factors triggers an inflammatory cascade of cytokine, chemokine, and inflammatory cell responses. Genes previously associated with SLE are&#x000a0;<italic toggle="yes">TYK2</italic>, <italic toggle="yes">IRF5, </italic>and <italic toggle="yes">CTLA4 and</italic>&#x000a0;confer an increased risk of developing DLE.</p>
        <p>An analysis of 405 patients by Bockle et al. found that smoking is highly associated with discoid lupus erythematosus. Bockle et al. hypothesized that smoking might play a pathogenic role in cutaneous lupus erythematosus variants (DLE, tumid lupus) by inducing apoptosis, stimulating T-cell proliferation, and increasing photosensitivity. Another explanation might be that smoking provokes DNA damage, resulting in the formation of DNA adducts and the production of ds-DNA antibodies. Keratinocytes may also participate in lupus skin damage by increasing the apoptotic rate and the production of proinflammatory cytokines such as IFN-alpha and IL-6 for SLE and IFN-lambda for DLE.<xref ref-type="bibr" rid="article-24528.r9">[9]</xref><xref ref-type="bibr" rid="article-24528.r10">[10]</xref></p>
      </sec>
      <sec id="article-24528.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The findings of histopathologic examination in cutaneous lupus vary based on the subtype. Overlap can be seen in the histologic findings among the various clinical phenotypes, particularly ACLE, SCLE, and discoid lesions. In cutaneous LE, basal cell damage (also referred to as vacuolar degeneration, hydropic change, or interface dermatitis) and lymphohistiocytic inflammatory infiltrates are commonly seen. In discoid lupus lesions, periadnexal inflammation, follicular plugging, and hyperkeratosis are primarily seen in addition to the interface dermatitis.<xref ref-type="bibr" rid="article-24528.r11">[11]</xref>Dermal mucinosis along with thickened basement membrane is usually noted.&#x000a0;</p>
        <p>Examination of the skin for deposits of immunoreactants is called direct immunofluorescence (DIF). DIF of lesional skin can be useful in establishing a diagnosis of cutaneous LE in cases&#x000a0;where routine histopathology is equivocal. DIF does not replace routine histologic staining as the method of choice for establishing a diagnosis. In active lesions of DLE, DIF of lesional skin is positive in the majority of cases. The most characteristic DIF finding in cutaneous LE is antibody deposition at the dermal-epidermal junction and around hair follicles. These deposits are typically granular, and they are composed primarily of IgG and/or IgM.<xref ref-type="bibr" rid="article-24528.r12">[12]</xref><xref ref-type="bibr" rid="article-24528.r13">[13]</xref></p>
        <p>The lupus band test (LBT) is a diagnostic procedure used to detect deposits of immunoglobulins and complement components along the dermo-epidermal junction in patients with lupus erythematosus (LE). LBT can help distinguish systemic lupus erythematosus from chronic lupus erythematosus because, in SLE patients, the LBT is frequently positive in both uninvolved and involved skin, whereas in CLE patients, only the involved skin is positive.<xref ref-type="bibr" rid="article-24528.r14">[14]</xref><xref ref-type="bibr" rid="article-24528.r15">[15]</xref>&#x000a0;The LBT is positive on the lesional skin in 75% of patients. Ideal lesions for LBT for DLE are on the head and neck that have been present for at least a few months.</p>
      </sec>
      <sec id="article-24528.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>DLE is the most common form of chronic cutaneous&#x000a0;erythematosus&#x000a0;and can occur as localized form (80%) with lesions on the face, ears, and scalp or as disseminated DLE (20%) with lesions above and below the neck. The disseminated form of DLE, especially when involving the trunk, is associated with an increased risk of progression to SLE up to 28%.<xref ref-type="bibr" rid="article-24528.r16">[16]</xref></p>
        <p>It is unusual for discoid lesions to present below the neck without lesions also being present above the neck. Occasionally, discoid lesions develop on mucosal surfaces, including the lips, nasal mucosa, conjunctivae, and genital mucosa.<xref ref-type="bibr" rid="article-24528.r5">[5]</xref> Some patients with discoid lesions exhibit a photodistribution. Sun exposure seems to play a role in the development of lesions. However, patients can have discoid lesions on the sun-protected skin, and there is no clear association between sun exposure and their development.</p>
        <p>The first morphological sign of DLE is a well-defined, annular erythematous patch or plaque of varying size followed by follicular hyperkeratosis, which is adherent to the skin. By removing the adherent scale, follicle-sized keratotic spikes similar to carpet tacks can be seen (&#x0201c;carpet tack sign&#x0201d;).<xref ref-type="bibr" rid="article-24528.r17">[17]</xref> The lesions slowly expand with active inflammation and hyperpigmentation at the periphery, leaving depressed central atrophy, scarring, telangiectasia, and hypopigmentation.<xref ref-type="bibr" rid="article-24528.r18">[18]</xref> DLE can progress to irreversible scarring alopecia on the scalp. Although uncommon, a squamous cell carcinoma can develop in a longstanding discoid lesion at 2 to 3 percent and is often associated with a poor prognosis.<xref ref-type="bibr" rid="article-24528.r19">[19]</xref></p>
        <p>Patients who present with discoid lesions may have associated arthralgias, but, over time, only approximately 10% to 20% of these patients eventually meet the classification criteria for SLE. Hyperkeratotic plaques that are verrucous are noted in hypertrophic DLE, a rare entity of DLE.<xref ref-type="bibr" rid="article-24528.r20">[20]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-24528.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>In the evaluation of DLE, the dermatologist should take a directed history, perform a cutaneous examination looking for signs of possible systemic disease. The diagnosis of DLE is made based on clinical features, but histology may be required to confirm the diagnosis.<xref ref-type="bibr" rid="article-24528.r21">[21]</xref><xref ref-type="bibr" rid="article-24528.r22">[22]</xref>&#x000a0;</p>
        <p>Autoantibodies to SSA/Ro, SSB/La, U1RNP, histones, and ssDNA, are common in patients with SLE, but they are not disease-specific. There are no other specific autoantibodies to differentiate the subtypes of CLE that are routinely used in practice. One further possible&#x000a0;target of auto-antibodies is annexin 1, which has been suggested to play an important role in preventing autoimmune diseases. A recent study found a significantly higher level of anti-annexin 1 antibodies in DLE patients, suggesting that anti-annexin 1 antibodies might be a new diagnostic marker for DLE. Anti-annexin 1 antibodies level in the serum did not correlate with DLE activity.<xref ref-type="bibr" rid="article-24528.r23">[23]</xref></p>
      </sec>
      <sec id="article-24528.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Early treatment of discoid lupus lesions may lead to the total clearing of skin lesions, but treatment failure results in permanent scarring. Hair loss, depressed scars, and pigmentary changes are often disfiguring, particularly in darker-skinned people. Some general measures, such as sun avoidance, avoidance of photosensitizing medications, and liberal application of sunscreen are encouraged because cutaneous lesions are known to be exacerbated by sunlight.<xref ref-type="bibr" rid="article-24528.r24">[24]</xref>&#x000a0;Smoking cessation is encouraged, as smoking can increase DLE disease activity. Studies demonstrate a statistically significant decrease in the efficacy of antimalarial medication in individuals who have currently&#x000a0;or ever smoked.<xref ref-type="bibr" rid="article-24528.r25">[25]</xref><xref ref-type="bibr" rid="article-24528.r26">[26]</xref><xref ref-type="bibr" rid="article-24528.r27">[27]</xref></p>
        <p>Current first-line treatment for DLE consists of photoprotection in conjunction&#x000a0;with topical or intralesional corticosteroids and topical calcineurin inhibitors.<xref ref-type="bibr" rid="article-24528.r28">[28]</xref> Chronic DLE lesions that are not responsive to topical therapy or have a widespread disease involvement are candidates for systemic therapy. When DLE is refractory to these measures, other agents with varying degrees of proven efficacy are used. Currently, no medications have been approved specifically,&#x000a0;and many of the drugs described in the literature were developed for use in&#x000a0;other autoimmune disorders.</p>
        <p>Acute exacerbations of DLE are treated with the application of a super high or high potency topical corticosteroid.<xref ref-type="bibr" rid="article-24528.r29">[29]</xref>&#x000a0;Clinical improvement is usually observed within 2 weeks of therapy. Treatment can be stopped when lesions are erythema or scale-free (signs of disease inactivity). Cutaneous atrophy is the major adverse effect with chronic use of topical corticosteroids. If the DLE lesion is refractory to high potency topical corticosteroid use for 2 to 4 weeks, alternative therapy with intralesional corticosteroid or topical calcineurin inhibitor should be initiated. Topical calcineurin inhibitors such as tacrolimus 0.1% or 0.03% ointment, pimecrolimus 1% cream are mostly utilized for facial lesions, as they do not cause atrophy.<xref ref-type="bibr" rid="article-24528.r30">[30]</xref>&#x000a0;They are more expensive and have a slow onset of action. Clinical improvement is typically noted within 4 weeks of therapy. Low potency topical corticosteroids or topical calcineurin inhibitors are typically used to maintain the DLE lesions in remission once the acute flare resolves.<xref ref-type="bibr" rid="article-24528.r31">[31]</xref>&#x000a0;Burning sensation after application that resolves within 1 to 2 weeks is the most common adverse effect of topical calcineurin inhibitors. Topical lesions that do not respond to the above therapy are treated with intralesional triamcinolone acetonide of 0.1 ml (3 to 5 mg/ml strength). Multiple injections into the lesion 1 cm apart should be given. Injections can be repeated every 3 to 4 weeks. If there is no clinical improvement after 2 to 3 injections, alternative treatment should be initiated. Dyspigmentation and atrophy of the skin are the common side effects of intralesional corticosteroids.&#x000a0;&#x000a0;&#x000a0;</p>
        <p>Antimalarials are immunotherapeutic and are considered first-line systemic therapy for CLE. Hydroxychloroquine (HCQ) and chloroquine with or without quinacrine are currently&#x000a0;utilized in the treatment of DLE. HCQ is preferred over chloroquine due to the lower risk of side effects, specifically retinal toxicity. Quinacrine is known to cause hematological abnormalities. Hydroxychloroquine is usually started at 200 mg/day and increased to 200 mg two times a day in 1 to 2 weeks if there are no side effects. The maximum dose of hydroxychloroquine should not exceed 5 mg/kg of real body weight per day, given&#x000a0;its association with retinal toxicity.<xref ref-type="bibr" rid="article-24528.r32">[32]</xref>&#x000a0;6 to 8 weeks of therapy is required to assess the effectiveness. Quinacrine at a dose of 100 mg/day is added to hydroxychloroquine if no clinical improvement is noted with hydroxychloroquine alone.<xref ref-type="bibr" rid="article-24528.r33">[33]</xref>&#x000a0;Chloroquine dose should not exceed 2.3 mg/kg of real body weight per day due to the risk of retinopathy.<xref ref-type="bibr" rid="article-24528.r32">[32]</xref>Hydroxychloroquine and Chloroquine should not be utilized together, given the cumulative retinal toxicity. Patients should receive baseline and periodic eye exams while on therapy. Blue-gray discoloration of face, shins, palate, and bleaching of light-colored hair may occur. Quinacrine use may lead to generalized yellow pigmentation of the skin, secretions, and sclera.&#x000a0;</p>
        <p>Other treatment modalities, such as retinoids, vitamin A analogs with anti-keratinizing and anti-inflammatory effects, are sometimes used in CLE, but documentation in the literature is limited. Topical retinoids such as tretinoin 0.05% cream or tazarotene 0.05% gel are utilized to treat hypertrophic DLE.<xref ref-type="bibr" rid="article-24528.r34">[34]</xref>&#x000a0;Topical retinoids are pregnancy category X drugs, and cutaneous irritation is a commonly observed adverse effect. Immunomodulators and Immunosuppressive agents such as methotrexate, systemic retinoids, dapsone, mycophenolate mofetil, azathioprine, intravenous immune globulin (IVIG), cyclophosphamide, and cyclosporine, have all been trialed in the treatment of DLE but thought to be second-line when refractory to other treatments.<xref ref-type="bibr" rid="article-24528.r35">[35]</xref></p>
        <p>Methotrexate at a dose range of 10 to 25 mg/week is utilized for DLE lesions. Clinical improvement is noted within 2 to 4 weeks of use, with the resolution of the lesions in about 6 to 8 weeks.<xref ref-type="bibr" rid="article-24528.r36">[36]</xref>&#x000a0;A dose of 5 to 10 mg of methotrexate is given as a test dose to assess if the patient can tolerate the drug. Liver function tests and complete blood count are followed 5 to 6 days after the drug administration to ensure no untoward side effects or intolerance to the medication. The most common side effects are gastrointestinal upset, hepatotoxicity, nephrotoxicity, teratogenicity, pulmonary fibrosis, bone marrow suppression, and oral ulcers. Folic acid supplements daily may minimize gastrointestinal side effects.<xref ref-type="bibr" rid="article-24528.r37">[37]</xref>&#x000a0;Mycophenolate mofetil is administered in doses of 1 to 3 gm/day. Gastrointestinal upset, cytopenias, and teratogenicity are some of the side effects of mycophenolate mofetil.</p>
        <p>Thalidomide, a potent teratogen, has been used in the treatment of DLE. An early report of its use in treating DLE of 60 individuals treated with 50 to 100 mg per day found complete or marked regression in 54 individuals (90%) with disease relapse in 71% of individuals with medication discontinuation.<xref ref-type="bibr" rid="article-24528.r38">[38]</xref> Side effects apart from teratogenicity include drowsiness, constipation, rash, edema, xeroderma, peripheral neuropathy, and thromboembolism.<xref ref-type="bibr" rid="article-24528.r39">[39]</xref> Lenalidomide is a thalidomide analog that may also prove useful in the treatment of DLE. Evidence suggests lenalidomide effectively treats DLE and has a less severe side effect profile than thalidomide but may be similarly limited by a tendency to relapse once discontinued. IVIG is given at a 2 g/kg dose and repeated every 4 to 8 weeks.<xref ref-type="bibr" rid="article-24528.r40">[40]</xref>&#x000a0;IVIG is expensive, and CLE lesions tend to recur with its use. Headache, renal failure, hypersensitivity reactions, thrombosis, vasculitis, and aseptic meningitis are some of the adverse effects of IVIG therapy.</p>
      </sec>
      <sec id="article-24528.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnoses of DLE include granuloma faciale, tinea faciei, cutaneous tuberculosis, cutaneous leishmaniasis, lymphoproliferative disorders, and sarcoidosis. DLE-induced scarring alopecia can be confused with lichen planopilaris, tinea capitis, and central centrifugal cicatricial alopecia. Hypertrophic DLE may be confused with keratoacanthoma, squamous cell cancer, hypertrophic lichen planus, and prurigo nodularis.</p>
      </sec>
      <sec id="article-24528.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>DLE lesions heal with scarring, atrophy, and dyspigmentation, causing more morbidity than mortality. Psychological functioning is affected by DLE lesions.<xref ref-type="bibr" rid="article-24528.r41">[41]</xref>&#x000a0;Exacerbations are associated with sun exposure and often occur in spring and summer. Localized DLE involving the scalp may lead to cicatricial alopecia. Generalized DLE is associated with the risk of progression to SLE in about 28 percent.<xref ref-type="bibr" rid="article-24528.r16">[16]</xref> Chronic DLE lesions in about 2 to 3 percent can progress to squamous cell carcinoma, which is usually associated with a poor prognosis.<xref ref-type="bibr" rid="article-24528.r19">[19]</xref>&#x000a0;Early detection and treatment of DLE lesions can minimize the associated morbidity.&#x000a0;</p>
      </sec>
      <sec id="article-24528.s12" sec-type="Complications">
        <title>Complications</title>
        <p>DLE and progression to SLE are associated with complications like</p>
        <list list-type="bullet">
          <list-item>
            <p>Cicatricial alopecia</p>
          </list-item>
          <list-item>
            <p>Pancytopenia</p>
          </list-item>
          <list-item>
            <p>Thromboembolism</p>
          </list-item>
          <list-item>
            <p>Arthritis</p>
          </list-item>
          <list-item>
            <p>Myositis</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Renal failure</p>
          </list-item>
          <list-item>
            <p>Neuropsychiatric manifestations like seizures, depression</p>
          </list-item>
          <list-item>
            <p>Pleuropericarditis</p>
          </list-item>
          <list-item>
            <p>Pancreatitis, mesenteric vasculitis</p>
          </list-item>
          <list-item>
            <p>Optic neuritis</p>
          </list-item>
          <list-item>
            <p>Therapy-related adverse effects</p>
          </list-item>
          <list-item>
            <p>Vitamin D deficiency&#x000a0;</p>
          </list-item>
        </list>
        <p>Periodic surveillance of DLE lesions and therapy-related side effects is crucial to avoid complications and promote clinical resolution.</p>
      </sec>
      <sec id="article-24528.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be educated about photoprotection and the possibility of developing skin lesions up to 3 weeks after sun exposure.<xref ref-type="bibr" rid="article-24528.r42">[42]</xref>&#x000a0;Using protective clothing and wide-brimmed hats, avoiding sun exposure in peak hours of 10:00 AM to 2:00 PM, generous application of sunscreen with at least sun protection factor of 30 against both UVA and UVB solar light, avoidance of photosensitizing medications, and avoiding outdoor occupations are highly recommended. Cessation of smoking and avoidance of alcohol is encouraged. Educating patients that nicotine interferes with antimalarial therapy uptake and hastens their metabolism helps them understand the rationale behind tobacco cessation.<xref ref-type="bibr" rid="article-24528.r43">[43]</xref>&#x000a0;Smoking cessation without nicotine replacement therapy is ideal. Patients are prone to vitamin D deficiency by minimizing sun exposure and sunscreen application; hence, it is recommended to counsel them on annual screening for vitamin D deficiency.<xref ref-type="bibr" rid="article-24528.r44">[44]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-24528.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Lupus is best managed by an interprofessional team of healthcare workers because the disorder can affect almost every organ in the body. Besides physicians, the role of the nurse, pharmacist, therapist, social worker, and mental health counselor is vital. The key is to stress the importance of medication compliance. Patients should be educated about the importance of&#x000a0;seeking help early when symptoms arise. At the first sign of renal dysfunction, medical help should be sought. Once renal failure is established, the only treatment is transplantation or dialysis. Patients should be told to avoid sunlight, stop smoking, eat healthily and remain active. Women of childbearing age should consult with an obstetrician before getting pregnant. Finally, joining a support group and/or following up with a mental health counselor is highly recommended.<xref ref-type="bibr" rid="article-24528.r45">[45]</xref><xref ref-type="bibr" rid="article-24528.r46">[46]</xref>&#x000a0;[Level&#x000a0;5]</p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>Discoid lupus is an unpredictable and highly variable disorder. While the condition is benign, it can cause devastating complications, often leading to high morbidity and a poor quality of life. The disorder frequently waxes and wanes. The outcome is much improved for patients with only skin and musculoskeletal involvement. The outcomes are worst for patients with CNS and renal involvement. Today, with treatment, there is an 80% survival at ten years, but failure to comply with treatment can lead to early death. At some point in time, the majority of lupus patients will develop hypertension, lipid disorders, diabetes, infections, osteoporosis, and malignancies like lymphomas and liver cancer. <xref ref-type="bibr" rid="article-24528.r47">[47]</xref><xref ref-type="bibr" rid="article-24528.r48">[48]</xref>&#x000a0;[Level&#x000a0;5]</p>
      </sec>
      <sec id="article-24528.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24528&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24528">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/lupus/discoid-lupus-erythematosus/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=24528">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24528/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24528">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-24528.s16">
        <fig id="article-24528.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Discoid Lupus, Scalp <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="discoid__lupus-01" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-24528.s17">
        <fig id="article-24528.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Linear Discoid Lupus Erythematosus Contributed by Dr. Shyam Verma, MBBS, DVD, FRCP, FAAD, Vadodara, India</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Linear__discoid__lupus__erythematosus__SV1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-24528.s18">
        <title>References</title>
        <ref id="article-24528.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Udompanich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chanprapaph</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Suchonwanit</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Hair and Scalp Changes in Cutaneous and Systemic Lupus Erythematosus.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>679</fpage>
            <page-range>679-694</page-range>
            <pub-id pub-id-type="pmid">29948959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dammacco</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Procaccio</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Racanelli</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vacca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dammacco</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Ocular Involvement in Systemic Lupus Erythematosus: The Experience of Two Tertiary Referral Centers.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2018</year>
            <volume>26</volume>
            <issue>8</issue>
            <fpage>1154</fpage>
            <page-range>1154-1165</page-range>
            <pub-id pub-id-type="pmid">30096011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abad&#x000ed;as-Granado</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Bernal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Felipo-Berlanga</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ara-Mart&#x000ed;n</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Coexistence of Tumid Lupus Erythematosus and Discoid Lupus Erythematosus.</article-title>
            <source>Actas Dermosifiliogr (Engl Ed)</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>110</volume>
            <issue>3</issue>
            <fpage>253</fpage>
            <page-range>253-255</page-range>
            <pub-id pub-id-type="pmid">30072022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sontheimer</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>The lexicon of cutaneous lupus erythematosus--a review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus.</article-title>
            <source>Lupus</source>
            <year>1997</year>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>84</fpage>
            <page-range>84-95</page-range>
            <pub-id pub-id-type="pmid">9061656</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salah</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Clinical and dermoscopic spectrum of discoid lupus erythematosus: novel observations from lips and oral mucosa.</article-title>
            <source>Int J Dermatol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>57</volume>
            <issue>7</issue>
            <fpage>830</fpage>
            <page-range>830-836</page-range>
            <pub-id pub-id-type="pmid">29700807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drenkard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aspey</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Helmick</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Bao</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Racial Disparities in the Incidence of Primary Chronic Cutaneous Lupus Erythematosus in the Southeastern US: The Georgia Lupus Registry.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>71</volume>
            <issue>1</issue>
            <fpage>95</fpage>
            <page-range>95-103</page-range>
            <pub-id pub-id-type="pmid">29669194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ga&#x000fc;z&#x000e8;re</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gerber</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Renou</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ferrandiz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bagny</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Osdoit</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yvin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Raffray</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>[Epidemiology of systemic lupus erythematosus in Reunion Island, Indian Ocean: A case-series in adult patients from a University Hospital].</article-title>
            <source>Rev Med Interne</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>214</fpage>
            <page-range>214-219</page-range>
            <pub-id pub-id-type="pmid">30041816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oh</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Ro</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Ten-year retrospective clinicohistological study of cutaneous lupus erythematosus in Korea.</article-title>
            <source>J Dermatol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>45</volume>
            <issue>4</issue>
            <fpage>436</fpage>
            <page-range>436-443</page-range>
            <pub-id pub-id-type="pmid">29423919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahn</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Deverapalli</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Rosmarin</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>JAK-STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis.</article-title>
            <source>Int J Dermatol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>57</volume>
            <issue>8</issue>
            <fpage>1007</fpage>
            <page-range>1007-1014</page-range>
            <pub-id pub-id-type="pmid">29873082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Two</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>So</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Paravar</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Discoid Lupus and Human Immunodeficiency Virus: A Retrospective Chart Review to Determine the Prevalence and Progression of Co-occurrence of these Conditions at a Single Academic Center.</article-title>
            <source>Indian J Dermatol</source>
            <year>2017</year>
            <season>Mar-Apr</season>
            <volume>62</volume>
            <issue>2</issue>
            <fpage>226</fpage>
            <pub-id pub-id-type="pmid">28400654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Werth</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous lupus erythematosus: a review.</article-title>
            <source>Dermatol Clin</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>373</fpage>
            <page-range>373-85, v</page-range>
            <pub-id pub-id-type="pmid">12170873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mutasim</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>BB</given-names>
              </name>
            </person-group>
            <article-title>Immunofluorescence in dermatology.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2001</year>
            <month>Dec</month>
            <volume>45</volume>
            <issue>6</issue>
            <fpage>803</fpage>
            <page-range>803-22; quiz 822-4</page-range>
            <pub-id pub-id-type="pmid">11712024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dahl</surname>
                <given-names>MV</given-names>
              </name>
            </person-group>
            <article-title>Usefulness of direct immunofluorescence in patients with lupus erythematosus.</article-title>
            <source>Arch Dermatol</source>
            <year>1983</year>
            <month>Dec</month>
            <volume>119</volume>
            <issue>12</issue>
            <fpage>1010</fpage>
            <page-range>1010-7</page-range>
            <pub-id pub-id-type="pmid">6360051</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harrist</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Mihm</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>The specificity and clinical usefulness of the lupus band test.</article-title>
            <source>Arthritis Rheum</source>
            <year>1980</year>
            <month>Apr</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>479</fpage>
            <page-range>479-90</page-range>
            <pub-id pub-id-type="pmid">6989372</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>George</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kurian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic evaluation of the lupus band test in discoid and systemic lupus erythematosus.</article-title>
            <source>Int J Dermatol</source>
            <year>1995</year>
            <month>Mar</month>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>170</fpage>
            <page-range>170-3</page-range>
            <pub-id pub-id-type="pmid">7751090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chong</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Determining risk factors for developing systemic lupus erythematosus in patients with discoid lupus erythematosus.</article-title>
            <source>Br J Dermatol</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>166</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-35</page-range>
            <pub-id pub-id-type="pmid">21910708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inamadar</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Perforation of paper with pen: Simple technique to explain the carpet tack sign in discoid lupus erythematosus.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>81</volume>
            <issue>6</issue>
            <fpage>e159</fpage>
            <page-range>e159-e160</page-range>
            <pub-id pub-id-type="pmid">30905795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rowell</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <article-title>Laboratory abnormalities in the diagnosis and management of lupus erythematosus.</article-title>
            <source>Br J Dermatol</source>
            <year>1971</year>
            <month>Mar</month>
            <volume>84</volume>
            <issue>3</issue>
            <fpage>210</fpage>
            <page-range>210-6</page-range>
            <pub-id pub-id-type="pmid">4102091</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaalberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moradi Tuchayi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ameri</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Ngo</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Eliane</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Livneh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Rosman</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Musiek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anadkat</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Demehri</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Chronic Inflammation Promotes Skin Carcinogenesis in Cancer-Prone Discoid Lupus Erythematosus.</article-title>
            <source>J Invest Dermatol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>139</volume>
            <issue>1</issue>
            <fpage>62</fpage>
            <page-range>62-70</page-range>
            <pub-id pub-id-type="pmid">30030152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farley-Loftus</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Elmariah</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Ralston</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kamino</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Franks</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Hypertrophic discoid lupus erythematosus.</article-title>
            <source>Dermatol Online J</source>
            <year>2010</year>
            <month>Nov</month>
            <day>15</day>
            <volume>16</volume>
            <issue>11</issue>
            <fpage>1</fpage>
            <pub-id pub-id-type="pmid">21163152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flynn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gilhooley</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>O'Shea</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wynne</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The use of SLICC and ACR criteria to correctly label patients with cutaneous lupus and systemic lupus erythematosus.</article-title>
            <source>Clin Rheumatol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>817</fpage>
            <page-range>817-818</page-range>
            <pub-id pub-id-type="pmid">29392510</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xie</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Elevated Serum Interleukin-34 Level in Patients with Systemic Lupus Erythematosus Is Associated with Disease Activity.</article-title>
            <source>Sci Rep</source>
            <year>2018</year>
            <month>Feb</month>
            <day>22</day>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>3462</fpage>
            <pub-id pub-id-type="pmid">29472590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kretz</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Norpo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abeler-D&#x000f6;rner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Linke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Haust</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Edler</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Krammer</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Kuhn</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Anti-annexin 1 antibodies: a new diagnostic marker in the serum of patients with discoid lupus erythematosus.</article-title>
            <source>Exp Dermatol</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>19</volume>
            <issue>10</issue>
            <fpage>919</fpage>
            <page-range>919-21</page-range>
            <pub-id pub-id-type="pmid">20701627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Callen</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Discoid lupus erythematosus--variants and clinical associations.</article-title>
            <source>Clin Dermatol</source>
            <year>1985</year>
            <season>Jul-Sep</season>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>49</fpage>
            <page-range>49-57</page-range>
            <pub-id pub-id-type="pmid">3880023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muangchan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>van Vollenhoven</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Bernatsky</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Inan&#x000e7;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rothfield</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Nash</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Furie</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Sen&#x000e9;cal</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Chandran</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Burgos-Vargas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ramsey-Goldman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pope</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Treatment Algorithms in Systemic Lupus Erythematosus.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>67</volume>
            <issue>9</issue>
            <fpage>1237</fpage>
            <page-range>1237-1245</page-range>
            <pub-id pub-id-type="pmid">25777803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Powers</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Systemic lupus erythematosus and discoid lupus erythematosus.</article-title>
            <source>Oral Maxillofac Surg Clin North Am</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>651</fpage>
            <page-range>651-62</page-range>
            <pub-id pub-id-type="pmid">18940631</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Franc&#x000e8;s</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bar&#x000e8;te</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Piette</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>[Dermatologic manifestations in lupus erythematosus].</article-title>
            <source>Rev Med Interne</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>9</issue>
            <fpage>701</fpage>
            <page-range>701-9</page-range>
            <pub-id pub-id-type="pmid">18562046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bjornberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hellgren</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Topical treatment of chronic discoid lupus erythematosus with betamethason-17-valerate and fluocinolone acetonie-a double blind study.</article-title>
            <source>Indian J Dermatol</source>
            <year>1966</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-8</page-range>
            <pub-id pub-id-type="pmid">5341750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jessop</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Whitelaw</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Delamere</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>Drugs for discoid lupus erythematosus.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2009</year>
            <month>Oct</month>
            <day>07</day>
            <issue>4</issue>
            <fpage>CD002954</fpage>
            <pub-id pub-id-type="pmid">19821298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tzellos</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Kouvelas</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>64</volume>
            <issue>4</issue>
            <fpage>337</fpage>
            <page-range>337-41</page-range>
            <pub-id pub-id-type="pmid">18157526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000e1;rdy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ruzicka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kuhn</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Topical calcineurin inhibitors in cutaneous lupus erythematosus.</article-title>
            <source>Arch Dermatol Res</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>301</volume>
            <issue>1</issue>
            <fpage>93</fpage>
            <page-range>93-8</page-range>
            <pub-id pub-id-type="pmid">18797893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marmor</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Kellner</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Melles</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Mieler</surname>
                <given-names>WF</given-names>
              </name>
              <collab>American Academy of Ophthalmology</collab>
            </person-group>
            <article-title>Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).</article-title>
            <source>Ophthalmology</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>123</volume>
            <issue>6</issue>
            <fpage>1386</fpage>
            <page-range>1386-94</page-range>
            <pub-id pub-id-type="pmid">26992838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cavazzana</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sala</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bazzani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ceribelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zane</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cattaneo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tincani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Calzavara-Pinton</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Franceschini</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.</article-title>
            <source>Lupus</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>18</volume>
            <issue>8</issue>
            <fpage>735</fpage>
            <page-range>735-9</page-range>
            <pub-id pub-id-type="pmid">19502270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seiger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Roland</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous lupus treated with topical tretinoin: a case report.</article-title>
            <source>Cutis</source>
            <year>1991</year>
            <month>May</month>
            <volume>47</volume>
            <issue>5</issue>
            <fpage>351</fpage>
            <page-range>351-5</page-range>
            <pub-id pub-id-type="pmid">2070657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuhn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ruland</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bonsmann</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous lupus erythematosus: update of therapeutic options part II.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>65</volume>
            <issue>6</issue>
            <fpage>e195</fpage>
            <page-range>e195-213</page-range>
            <pub-id pub-id-type="pmid">20800319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wenzel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Br&#x000e4;hler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bieber</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>T&#x000fc;ting</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients.</article-title>
            <source>Br J Dermatol</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>153</volume>
            <issue>1</issue>
            <fpage>157</fpage>
            <page-range>157-62</page-range>
            <pub-id pub-id-type="pmid">16029342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ortiz</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Shea</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Suarez-Almazor</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Moher</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Tugwell</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials.</article-title>
            <source>J Rheumatol</source>
            <year>1998</year>
            <month>Jan</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>36</fpage>
            <page-range>36-43</page-range>
            <pub-id pub-id-type="pmid">9458200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pelle</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Werth</surname>
                <given-names>VP</given-names>
              </name>
            </person-group>
            <article-title>Thalidomide in cutaneous lupus erythematosus.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2003</year>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>379</fpage>
            <page-range>379-87</page-range>
            <pub-id pub-id-type="pmid">12762830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chasset</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tounsi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cesbron</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barbaud</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Franc&#x000e8;s</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Arnaud</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>78</volume>
            <issue>2</issue>
            <fpage>342</fpage>
            <page-range>342-350.e4</page-range>
            <pub-id pub-id-type="pmid">28989111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000e9;n&#x000e9;reau</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chosidow</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Danel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ch&#x000e9;rin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Herson</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>High-dose intravenous immunoglobulin in cutaneous lupus erythematosus.</article-title>
            <source>Arch Dermatol</source>
            <year>1999</year>
            <month>Sep</month>
            <volume>135</volume>
            <issue>9</issue>
            <fpage>1124</fpage>
            <page-range>1124-5</page-range>
            <pub-id pub-id-type="pmid">10490126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Broadbent</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Coomarasamy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jarrett</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Illness perception in association with psychological functioning in patients with discoid lupus erythematosus.</article-title>
            <source>Br J Dermatol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>173</volume>
            <issue>3</issue>
            <fpage>824</fpage>
            <page-range>824-6</page-range>
            <pub-id pub-id-type="pmid">25639859</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuhn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sonntag</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Richter-Hintz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Oslislo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Megahed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ruzicka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lehmann</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Phototesting in lupus erythematosus: a 15-year experience.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2001</year>
            <month>Jul</month>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>86</fpage>
            <page-range>86-95</page-range>
            <pub-id pub-id-type="pmid">11423840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wozniacka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McCauliffe</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit.</article-title>
            <source>Lupus</source>
            <year>2002</year>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>71</fpage>
            <page-range>71-81</page-range>
            <pub-id pub-id-type="pmid">11958581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cusack</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Danby</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fallon</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>O'Kelly</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ambrose</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kearns</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus.</article-title>
            <source>Photodermatol Photoimmunol Photomed</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>260</fpage>
            <page-range>260-7</page-range>
            <pub-id pub-id-type="pmid">18811868</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuhn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Landmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wenzel</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Advances in the treatment of cutaneous lupus erythematosus.</article-title>
            <source>Lupus</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>25</volume>
            <issue>8</issue>
            <fpage>830</fpage>
            <page-range>830-7</page-range>
            <pub-id pub-id-type="pmid">27252259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meller</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Homey</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ruzicka</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Socioeconomic factors in lupus erythematosus.</article-title>
            <source>Autoimmun Rev</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>242</fpage>
            <page-range>242-6</page-range>
            <pub-id pub-id-type="pmid">15893719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jessop</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Whitelaw</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Grainge</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Jayasekera</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Drugs for discoid lupus erythematosus.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>May</month>
            <day>05</day>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>CD002954</fpage>
            <pub-id pub-id-type="pmid">28476075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24528.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drucker</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mussani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Siddha</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Gladman</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Urowitz</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Prognostic implications of active discoid lupus erythematosus and malar rash at the time of diagnosis of systemic lupus erythematosus: Results from a prospective cohort study.</article-title>
            <source>Lupus</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>376</fpage>
            <page-range>376-81</page-range>
            <pub-id pub-id-type="pmid">26453664</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
